{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:17:49Z","timestamp":1770891469815,"version":"3.50.1"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1001\/jamacardio.2018.3957","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T16:31:22Z","timestamp":1543422682000},"page":"1226","source":"Crossref","is-referenced-by-count":45,"title":["Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With  Reduced Ejection Fraction"],"prefix":"10.1001","volume":"3","author":[{"given":"Pratyaksh K.","family":"Srivastava","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, University of California Los Angeles Medical Center, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[{"name":"Montreal Heart Institute, University de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles Medical Center, Los Angeles"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"11","key":"hbr180027r1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"hbr180027r2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","article-title":"A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"hbr180027r3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"issue":"9169","key":"hbr180027r4","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).","volume":"353","author":"Group M-HS","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"hbr180027r5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms.","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"hbr180027r6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"issue":"25","key":"hbr180027r7","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure.","volume":"363","author":"Tang","year":"2010","journal-title":"N Engl J Med"},{"issue":"9386","key":"hbr180027r8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"hbr180027r9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","article-title":"Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"hbr180027r10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"issue":"20","key":"hbr180027r11","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.282.20.1899","article-title":"Gauging the impact of statins using number needed to treat.","volume":"282","author":"Kumana","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"hbr180027r12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction.","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"5","key":"hbr180027r13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction.","volume":"4","author":"King","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"23","key":"hbr180027r14","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMc1509753","article-title":"Estimating the long-term treatment benefits of sacubitril-valsartan.","volume":"373","author":"Claggett","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"hbr180027r15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamacardio.2016.1724","article-title":"Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure.","volume":"1","author":"Fonarow","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"6","key":"hbr180027r16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/jamacardio.2018.0398","article-title":"Effects of sacubitril\/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial.","volume":"3","author":"Chandra","year":"2018","journal-title":"JAMA Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2716298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T19:07:57Z","timestamp":1545246477000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.3957"}},"subtitle":["An Analysis of Data From the PARADIGM-HF Trial"],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.3957","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,1]]}}}